Tel Aviv: (HRNW) Pfizer-BioNTech’s COVID-19 vaccine appears to reduce symptomatic coronavirus infections by more than 90 per cent in the real world, according to Israeli researchers.
The preliminary findings published on Monday suggest that the vaccine remains remarkably effective in a mass vaccination campaign — outside the carefully controlled conditions of a clinical trial.
The Clalit Research Institute analysed data on 1.2 million people, about half of whom had received the Pfizer-BioNTech vaccine. Researchers compared patients who received the vaccine with similar individuals who hadn’t.
The rate of symptomatic COVID-19 — meaning people who were infected with the coronavirus and felt sick — decreased by 94 per cent among people who received two doses of the vaccine, according to a press release from Clalit. The rate of serious illness decreased by 92 per cent.